Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.)(Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.))

概要

基本信息

药物类型

溶瘤病毒

别名

MV NIS、MVNIS、Sodium Iodide Simporter Measles Virus

+ [2]

靶点

NIS

作用机制

NIS调节剂(solute carrier family 5 member 5 modulators)、免疫调节剂

治疗领域

肿瘤免疫系统疾病心血管疾病+ [6]

在研适应症

输卵管癌多发性骨髓瘤卵巢癌+ [5]

非在研适应症

胶质母细胞瘤头颈部肿瘤转移性非小细胞肺癌+ [1]

原研机构

Vyriad, Inc.初创企业

在研机构

Vyriad, Inc.初创企业

非在研机构

University of Arkansas System

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

9

项与 Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) 相关的临床试验

NCT03171493 / Completed临床1期

Neoadjuvant Intravesical NIS Measles Virus (MV-NIS) in Patients Undergoing Cystectomy for Urothelial Carcinoma But Ineligible for Neoadjuvant Cisplatin-based Chemotherapy

This is a Phase 1 study designed to test the tolerability and feasibility of intravesical therapy with an attenuated Measles virus (MV-NIS) in patients with urothelial carcinoma who are undergoing radical cystectomy but are ineligible or do not desire neoadjuvant chemotherapy.

开始日期2018-07-20

申办/合作机构

Vyriad, Inc.初创企业

[+1]

NCT02919449 / Terminated临床1期

Phase 1 Dose Escalation Trial of Intra-Tumoral Injection of Sodium Iodide Simporter (NIS) Measles Virus (Edmonston Strain) in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with Atezolizumab in patients with recurrent and metastatic NSCLC.

开始日期2017-08-03

申办/合作机构

Vyriad, Inc.初创企业

NCT02700230 / Recruiting临床1期

Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor

This phase I trial studies the side effects and the best dose of a vaccine therapy in treating patients with malignant peripheral nerve sheath tumor that cannot be removed by surgery (unresectable) or has come back after a period of improvement (recurrent). Vaccines made from a gene-modified virus may kill tumor cells expressing a gene called neurofibromin 1 (NF1) without affecting surrounding normal cells and may also help the body build an effective immune response to kill tumor cells.

开始日期2017-03-22

申办/合作机构

Mayo Clinic

[+1]

100 项与 Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) 相关的专利（医药）

登录后查看更多信息

16

项与 Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) 相关的文献（医药）

2020-12-01·Leukemia1区 · 医学

Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma

1区 · 医学

Article

作者: Packiriswamy, Nandakumar ; Peng, Kah-Whye ; Zhou, Yumei ; Rooney, Cliona M ; Dispenzieri, Angela ; Diaz, Rosa M ; Russell, Stephen J ; Miller, Amber ; Upreti, Deepak ; Khan, Rehan

AbstractOncolytic virus therapy leads to immunogenic death of virus-infected tumor cells and this has been shown in preclinical models to enhance the cytotoxic T-lymphocyte response against tumor-associated antigens (TAAs), leading to killing of uninfected tumor cells. To investigate whether oncolytic virotherapy can increase immune responses to tumor antigens in human subjects, we studied T-cell responses against a panel of known myeloma TAAs using PBMC samples obtained from ten myeloma patients before and after systemic administration of an oncolytic measles virus encoding sodium iodide symporter (MV-NIS). Despite their prior exposures to multiple immunosuppressive antimyeloma treatment regimens, T-cell responses to some of the TAAs were detectable even before measles virotherapy. Measurable baseline T-cell responses against MAGE-C1 and hTERT were present. Furthermore, MV-NIS treatment significantly (P < 0.05) increased T-cell responses against MAGE-C1 and MAGE-A3. Interestingly, one patient who achieved complete remission after MV-NIS therapy had strong baseline T-cell responses both to measles virus proteins and to eight of the ten tested TAAs. Our data demonstrate that oncolytic virotherapy can function as an antigen agnostic vaccine, increasing cytotoxic T-lymphocyte responses against TAAs in patients with multiple myeloma, providing a basis for continued exploration of this modality in combination with immune checkpoint blockade.

2017-12-01·Leukemia1区 · 医学

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

1区 · 医学

Article

作者: Lacy, M Q ; Gertz, M A ; Lowe, V J ; Zhou, Y ; Laumann, K ; Peng, K-W ; Federspiel, M J ; Buadi, F ; LaPlant, B ; Dispenzieri, A ; Tong, C ; Dingli, D ; O'Connor, M ; Hayman, S ; Russell, S J

MV-NIS is an Edmonston lineage oncolytic measles virus expressing the human sodium iodide symporter-a means for monitoring by non-invasive imaging of radioiodine. Patients with relapsed, refractory myeloma who had explored all other treatment options were eligible for this Phase I trial. Cohort 1 was treated with intravenous MV-NIS, and Cohort 2 received cyclophosphamide 2 days prior to MV-NIS. Thirty-two patients were treated. Cohort 1 initially enrolled to four dose levels without reaching maximum tolerated dose (MTD) and subsequently to two higher dose levels when improved virus manufacture technology made it possible. MTD was not reached in Cohort 1, and TCID₅₀ 10¹¹ is the dose being used in a Phase II trial of single agent MV-NIS. Grade 3-4 adverse events in both cohorts at all dose levels were: neutropenia (n=9); leukocyte count decreased (n=5); thrombocytopenia (n=2); and CD4 lymphocytes decreased, anemia and lymphopenia (each n=1). MV-N RNA sequences were amplified from gargle specimens, blood and urine. ¹²³I scans were positive in eight patients. One patient achieved a complete response; transient drops in serum free light chains were seen in other patients. MV-NIS is capable of replicating before being cleared by the immune system. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated myeloma.

2016-12-01·Human Gene Therapy Clinical Development3区 · 医学

Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko Mice

3区 · 医学

Article

作者: Ma, Hong ; Phillips, Joanna J. ; Jenks, Nathan ; Lal, Sangeet ; Peng, Kah-Whye ; Steele, Michael B. ; Kohanbash, Gary ; Raffel, Corey

The modified Edmonston vaccine strain of measles virus (MV) has shown potent oncolytic efficacy against various tumor types and is being investigated in clinical trials. Our laboratory showed that MV effectively kills medulloblastoma tumor cells in both localized disease and when tumor cells are disseminated through cerebrospinal fluid (CSF). Although the safety of repeated intracerebral injection of modified MV in rhesus macaques has been established, the safety of administering MV into CSF has not been adequately investigated. In this study, we assessed the safety of MV-NIS (MV modified to express the human sodium iodide symporter protein) injected into the CSF of measles-immunized and measles virus-susceptible transgenic (CD46, IFNαRko) mice. Treated animals were administered a single intraventricular injection of 1 × 10⁵ or 1 × 10⁶ TCID₅₀ (50% tissue culture infective dose) of MV-NIS. Detailed clinical observation was performed over a 90-day period. Clinically, we did not observe any measles-related toxic effects or behavioral abnormality in animals of any treated cohort. The complete blood count and blood chemistry analysis results were found to be within normal range for all the cohorts. Histologic examination of brains and spinal cords revealed inflammatory changes, mostly related to the needle track; these resolved by day 21 postinjection. To assess viral biodistribution, quantitative RT-PCR to detect the measles virus N-protein was performed on blood and brain samples. Viral RNA was not detectable in the blood as soon as 2 days after injection, and virus cleared from the brain by 45 days postadministration in all treatment cohorts. In conclusion, our data suggest that a single injection of modified MV into the CSF is safe and can be used in future therapeutic applications.

100 项与 Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.)	-	-

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
间皮瘤	申请上市	美国	-	-
输卵管癌	临床2期	-	Vyriad, Inc.初创企业	-
多发性骨髓瘤	临床2期	-	Vyriad, Inc.初创企业	-
卵巢癌	临床2期	-	Vyriad, Inc.初创企业	-
腹膜癌	临床2期	-	Vyriad, Inc.初创企业	-
乳腺癌	临床1期	-	Vyriad, Inc.初创企业	-
胶质母细胞瘤	临床1期	美国	Vyriad, Inc.初创企业	-
头颈部肿瘤	临床1期	美国	Vyriad, Inc.初创企业	-
间皮瘤	临床1期	-	Vyriad, Inc.初创企业	-
横纹肌肉瘤	临床1期	-	Vyriad, Inc.初创企业	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02919449 (CTgov)	临床1期	复发性非小细胞肺癌 \| 转移性非小细胞肺癌	2	atezolizumab+MV-NIS	窪製齋選積廠醖積獵膚(顧網積顧廠壓糧廠夢壓) = 築廠積願醖憲範膚繭鹹餘醖鏇夢鬱範構簾蓋糧 (鏇醖廠餘壓窪憲膚選觸, 鬱糧選顧艱襯憲範窪膚 ~ 繭夢餘餘夢鹹艱糧醖憲) 更多	-	2023-07-21
NCT03171493 (ASCO_GU2022) 人工标引	临床1期	尿路上皮癌新辅助	8	MV-NIS	(齋簾鬱鏇簾艱廠構糧繭) = Only a single Adverse Event (AE) attributable to MV-NIS treatment (Grade 1 hematuria) 構憲鏇憲積艱衊繭鹹觸 (襯淵膚窪鑰膚艱鏇窪淵 )	积极	2022-02-16
NCT02192775 (CTgov)	临床2期	浆细胞骨髓瘤难治	2	MV-NIS	壓襯觸顧壓網鹽鹽襯積(鏇構夢淵選壓觸齋簾鏇) = 積壓鏇襯壓構壓醖壓艱製憲膚範鑰選積築夢艱 (網蓋糧膚獵築糧構壓鏇, 窪蓋構膚廠製鏇蓋簾鑰 ~ 鹹選膚蓋鏇簾繭糧膚鹽) 更多	-	2020-10-19
WCLC2016	N/A	恶性胸膜间皮瘤二线	12	MV-NIS	(簾窪窪齋繭淵鑰願網簾) = 獵鬱淵願艱選憲壓範齋衊網糧廠憲積齋鹹淵網 (遞醖夢遞觸餘製顧積積, 221, 484)	-	2016-12-06